Hypertrophic cardiomyopathy

Related records

Broader conditions (9)

• Cardiomyopathy
• Cardiovascular disorder
• Disease
• Disease by body system or component
• Heart disorder
• Human disease
• Intrinsic cardiomyopathy
• Muscle tissue disorder
• Musculoskeletal system disorder

Narrower conditions (103)

• 46,XY complete gonadal dysgenesis
• 46,XY disorder of sex development due to testicular 17,20-desmolase deficiency
• 46,XY gonadal dysgenesis-motor and sensory neuropathy syndrome
• 46,XY sex reversal 1
• 46,XY sex reversal 10
• 46,XY sex reversal 11
• 46,XY sex reversal 2
• 46,XY sex reversal 3
• 46,XY sex reversal 4
• 46,XY sex reversal 5
• 46,XY sex reversal 6
• 46,XY sex reversal 7
• 46,XY sex reversal 9
• AL amyloidosis
• Beckwith-Wiedemann syndrome
• Beckwith-Wiedemann syndrome due to 11p15 microdeletion
• Beckwith-Wiedemann syndrome due to 11p15 microduplication
• Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion
• Beckwith-Wiedemann syndrome due to CDKN1C mutation
• Beckwith-Wiedemann syndrome due to imprinting defect of 11p15

Trials (344)

• 3D Non-invasive Myocardial Electrical Propagation Mapping as a New Tool to Predict Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy
• 4D-flow MRI to Assess Left Ventricular Obstruction in Hypertrophic Cardiomyopathy
• A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease
• A Biomarker and MRI Study on Troponin Release After Exercise in Hypertrophic Cardiomyopathy
• A Cardiac Disease Quality of Life Study
• A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy
• A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy
• A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
• A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
• A Noninterventional, Single-Center Feasibility Study to Evaluate Measures of Heart Failure Risk
• A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
• A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy
• A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
• A Pilot Project Exploring the Impact of Whole Genome Sequencing in Healthcare
• A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy
• A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
• A Real-world HCM-cohort Trial
• A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population
• A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
• A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

Approved drugs (1)

• Mavacamten

Drugs in development (21)

• Acetylcysteine Phase 1
• Aficamten Phase 3
• Amlodipine Phase 2
• Aspirin Phase 3
• Atorvastatin Phase 3
• Candesartan Phase 2
• Delocamten Phase 2
• Diltiazem Phase 2
• Eleclazine Phase 2
• Losartan Phase 2
• Metoprolol succinate Phase 3
• Ninerafaxstat Phase 2
• Perhexiline Phase 3
• Pirfenidone Phase 2
• Rivaroxaban Phase 3
• Sacubitril Phase 2
• Sodium nitrate Phase 1
• Sotagliflozin Phase 3
• Trientine Phase 2
• Trimetazidine Phase 2

Other linked drugs (1)

• Henagliflozin